Ten Best Readings
Ten Best Readings in Gynecologic Cancer
William S. Roberts, MD
Program Leader, Gynecologic Oncology Program
H. Lee Moffitt Cancer Center & Research Institute
Kurman RJ, Henson DE, Herbst AL, et al. Interim guidelines for management of abnormal
cervical cytology: the 1992 National Cancer Institute Workshop. JAMA. 1994;271:1866-1869.
The authors present an excellent review with state-of-the-art guidelines for clinicians to
use to follow up low-grade cervical abnormalities.
van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after
induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J
Med. 1995;332:629-634.
This is one of the few randomized studies to investigate the effects of debulking surgery
on prognosis in patients with ovarian cancer.
McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared
with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N
Engl J Med. 1996;334:1-6.
The key study that shows the positive impact on survival of patients with ovarian cancer
when paclitaxel is added to cisplatin.
Brown D, Roberts JA, Elkins TE, et al. Hard choices: the gynecologic cancer
patient's end-of-life preferences. Gynecol Oncol. 1994:55;355-362.
This important study from Michigan details gynecologic oncology patients' preferences
about terminal care.
Chen F, Trapido EJ, Davis K. Differences in stage at presentation of breast and
gynecologic cancers among whites, blacks, and Hispanics. Cancer. 1994;73:2838-2842.
The percentage of early-stage diagnoses for breast cancer was lower among blacks and
Hispanic whites than non-Hispanic whites, suggesting that screening programs need to be
targeted differently for specific age and ethnic groups.
Shillitoe EJ, Kamath P, Chen Z. Papillomaviruses as targets for cancer gene therapy.
Cancer Gene Therapy. 1994;1:193-204.
Several approaches are described for developing specific gene therapy for cancers related
to human papilloma viruses.
Bastin K, Buchler D, Stitt J, et al. Resource utilization: high-dose versus low-dose
rate brachytherapy for gynecologic cancer. J Clin Oncol. 1993;16:256-263.
This report from a group of private and academic centers compares cost and other outcomes
for different dose rates for gynecologic brachytherapy. High-dose rate therapy generated a
"cost-shift" to radiotherapy departments.
Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and
ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66-71.
The identification of the 17q-linked BRCA1 breast and ovarian cancer susceptibility gene
is presented in this key report. The pace of development of markers of individual cancer
risk is accelerating.
Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and
endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85:304-313.
Thirty studies confirm that endometrial cancer risk increases with longer duration of
unopposed estrogen use, but data regarding risk among estrogen plus progestin users are
limited and conflicting.
Robinson DC, Bloss JD, Schiano MA. A retrospective study of tamoxifen and endometrial
cancer in breast cancer patients. Gynecol Oncol. 1995;59:186-190.
This article, with others, documents the effects of tamoxifen in promoting endometrial
cancer in patients with breast cancer.
Back to Cancer Control Journal Volume 3 Number 2